MK 8931 in both EPOCH and APECS studies for Alzheimer's disease-Merck Inc.
A data monitoring committee has looked at interim safety data from the Phase II/III EPOCH study of MK 8931 from Merck Inc., which included a safety cohort of 200 patients with mild to moderate Alzheimer's disease treated with the drug for at least three months. Based upon the DMC�s recommendations, Merck will continue enrollment of the EPOCH study and will initiate dosing in a new Phase III study (called APECS) evaluating MK-8931 in patients with prodromal Alzheimer's that is, amnestic mild cognitive impairment due to Alzheimer's.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.